Message

A novel endoscopic device, ForePass (Keyron), demonstrated superior metabolic effects compared with semaglutide in preclinical testing. 12 young Landrace pigs underwent ForePass implantation, semaglutide treatment or sham endoscopy with a 1-month follow-up period. ForePass limited weight gain to +4.3%, compared with +36% in semaglutide-treated pigs and +47% in controls, without affecting linear growth. Food intake decreased by 26% with ForePass versus 18.5% with semaglutide. The device induced a near-flat glycaemic response and markedly improved insulin sensitivity (SI=2.75±0.37 pM–¹·min–¹), while semaglutide and sham produced only modest effects. These findings support clinical testing of ForePass as a minimally invasive, reversible approach for metabolic modulation.

In more detail

Metabolic surgery has achieved major therapeutic goals, including long-term remission of type 2 diabetes mellitus (T2DM)1–3 and resolution of metabolic dysfunction-associated steatohepatitis.4 Procedures such as biliopancreatic diversion (BPD) and Roux-en-Y gastric bypass provide profound and durable improvements…